Premium
Oxaliplatin‐based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients
Author(s) -
Frenel JeanSebastien,
Leux Christophe,
Pouplin Luc,
Ferron Gwenael,
BertonRigaud Dominique,
Bourbouloux Emmanuelle,
Dravet François,
Jaffre Isabelle,
Classe JeanMarc
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21732
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , oxaliplatin , conventional pci , ovarian cancer , chemotherapy , surgery , oncology , cytoreductive surgery , cancer , colorectal cancer , myocardial infarction
Abstract Background The feasibility and safety of oxaliplatin‐based hyperthermic intraperitoneal chemotherapy (HIPEC) associated with cytoreductive surgery (CRS) was assessed in patients with peritoneal carcinomatosis resulting from primary advanced or relapsing epithelial ovarian cancer (EOC). Methods Thirty‐one patients received neoadjuvant platin‐based chemotherapy followed by oxaliplatin‐based HIPEC associated with CRS as consolidation of primary therapy (n = 19) or for relapsing disease (n = 12). Grade 3/4 complications were recorded according to National Cancer Institute definitions. Results Median peritoneal carcinomatosis index (PCI) was 2.7 after neoadjuvant chemotherapy. Mean duration of surgery was 352 min (range 105–614) and median hospital stay was 11 days (range 6–87). Grade 3 toxicity was observed in nine patients: five required repeat surgery, two an invasive procedure, four rehospitalization, and three a return to the ICU. No grade 4 toxicity occurred, excepted one hypokalemia. Median progression‐free survival (PFS) for primary advanced EOC was 13.2 months and 1‐year PFS was 59.3%. Median PFS for relapsing patients was 14.3 months and 1‐year PFS was 54.4%. Conclusion CRS with oxaliplatin‐based HIPEC is feasible and relatively safe in recurrent and primary EOC. HIPEC after neoadjuvant chemotherapy reduces the PCI and decreases the number of surgical procedures and morbidity. Further evaluations of this procedure are required to assess the survival benefits. J. Surg. Oncol. 2011;103:10–16. © 2010 Wiley‐Liss, Inc.